This post was originally published on this site
Investing.com — Moderna (NASDAQ:MRNA) dropped 14% after AstraZeneca (NYSE:AZN) and and Oxford said a vaccine candidate showed promise.
The Lancet reported that the vaccine “showed an acceptable safety profile, and homologous boosting increased antibody responses.”
Moderna has surged in recent months on vaccine news, quadrupling since March.
